Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or
sargramostim works in treating patients with breast cancer. Vaccines made from peptide or
antigen and/or a person's white blood cells mixed with tumor proteins may help the body build
an effective immune response to kill tumor cells that express breast cancer. It is not yet
known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating
patients with breast cancer.


Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure


Breast Ductal Carcinoma In Situ


Elizabeth A Mittendorf

See list of participating sites